New drugs with antifungal action need to be developed. Here, the authors investigate the antifungal activity of MOL3, a small molecule that was selected by virtual screening, against Candida spp.
Browsing: Basic > Drug Development
This research reports the synthesis of capped gold nanoparticles by reducing HAuCl4 with flower and leaf extracts of Ocimum tenuiflorum, leaves of Azadirachta indica and Mentha spicata and peel of Citrus sinensis plants and assessed their activity on Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumoniae.
A novel CRISPR–Cas9-based gene drive platform has been developed by researchers and may help us understand some of the genetic networks underlying virulence in fungal pathogen, Candida albicans.
Researchers have developed novel antimicrobials, such as metal-complexes, that could be used to treat infections – either as alternatives or supplements to traditional antibiotics – caused by multidrug-resistant bacteria.
Despite significant advances in the treatment of human immunodeficiency virus (HIV), there remain challenges. This review highlights recent advances in the application of nanotechnology to drug delivery, specifically with the purpose of improving HIV therapy.
MedChemNet and Infectious Diseases Hub recently attended the first two days of the 19th RSC / SCI Medicinal Chemistry Symposium. Here, you can catch up on the session delving into drug discovery for the neglected tropical diseases.
Ahead of the Call to Action on Antimicrobial Resistance in Berlin the UK’s Chief Medical Officer, Sally Davies, spoke about the need to ensure antimicrobial resistance stays on the political agenda, and the role of the individual in achieving this, at Antibiotic Research UK’s annual lecture.
Silver nanoparticles have long been used as potent antibacterial agents. However, toxicity concerns of silver nanoparticles have limited their successful clinical applications. This research reports a simple and cost-effective method for the synthesis of nickel-prussian blue@silver nanocomposites.
Researchers have uncovered the pharmacodynamic properties of novel antifungal, F901318, taking it one step closer to testing in clinical trials
Researchers have developed a novel compound, L-HIPPO, which can prevent viral budding in HIV-infected cells. It has been suggested this compound could supplement existing ‘kick and kill’ strategies, allowing complete eradication of HIV in the body.